A π-CLCL Type Immittance Converter for Constant Current and Dynamic Load Applications

Impedance-admittance converter is shortly termed as immittance converter. In this converter, the output current is proportional to the input voltage and the output voltage is proportional to the input current. The output current is thus independent of the load. This research evaluates the characteristics of a proposed π-CLCL immittance converter, which is a combination of the typical π- and T-type configurations, for constant current and dynamic load applications. The input-output characteristics and efficiency characteristics are analyzed and simulated. The characteristics are compared to that of the typical π- and T-type converters. The input-output characteristics and efficiency characteristics are then examined experimentally. It is observed that the experimental results agree with those of the simulation ones, and confirm that the π-CLCL configuration is more efficient than the typical π- and T-type immittance converters while maintaining a nearly constant output current and thus applicable for dynamic loads.DOI:http://dx.doi.org/10.11591/ijece.v4i5.595

In vivo Imaging of Intact Drosophila Larvae at Sub-cellular Resolution

Recent improvements in optical imaging, genetically encoded fluorophores and genetic tools allowing efficient establishment of desired transgenic animal lines have enabled biological processes to be studied in the context of a living, and in some instances even behaving, organism. In this protocol we will describe how to anesthetize intact Drosophila larvae, using the volatile anesthetic desflurane, to follow the development and plasticity of synaptic populations at sub-cellular resolution1-3. While other useful methods to anesthetize Drosophila melanogaster larvae have been previously described4,5,6,7,8, the protocol presented herein demonstrates significant improvements due to the following combined key features: (1) A very high degree of anesthetization; even the heart beat is arrested allowing for lateral resolution of up to 150 nm1, (2) a high survival rate of > 90% per anesthetization cycle, permitting the recording of more than five time-points over a period of hours to days2 and (3) a high sensitivity enabling us in 2 instances to study the dynamics of proteins expressed at physiological levels. In detail, we were able to visualize the postsynaptic glutamate receptor subunit GluR-IIA expressed via the endogenous promoter1 in stable transgenic lines and the exon trap line FasII-GFP1. (4) In contrast to other methods4,7 the larvae can be imaged not only alive, but also intact (i.e. non-dissected) allowing observation to occur over a number of days1. The accompanying video details the function of individual parts of the in vivo imaging chamber2,3, the correct mounting of the larvae, the anesthetization procedure, how to re-identify specific positions within a larva and the safe removal of the larvae from the imaging chamber

Erratum to: Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients (J Endocrinol Invest, 10.1007/s40618-016-0468-y)

Unfortunately, Prof. Mehdizadeh name was wrongly published in the original article. The complete correct name is Prof. M. Mehdizadeh. © 2016, Italian Society of Endocrinology (SIE)

TM NONLINEAR ELECTROMAGNETIC WAVES IN SEMICONDUCTOR SUPERLATICES WAVEGUIDING SYSTEMS

Considerable attention has been devoted to a nonlinear waves propagation in various wave-guide structure due to their applications in photonic-microwave devices . In this communication, the dispersion characteristics of transverse magnetic polarized waves nonlinear guided waves propagating in a multilayer semiconductor superlattices waveguide surrounded by one side by a nonlinear magnetic cover have been investigated theoretically. The two sublattice uniaxial antiferromagnetic crystal is considered as a nonlinear magnetic medium where the permeability is treated as a function of the magnetic field. Nummerical results are demonstrated for a waveguiding system containing some number of layers of superlattices. We hope that our present work could lead to several extensions and promising applications in future technology

Chitosan biopolymer improves the fruit quality of litchi (Litchi chinensis Sonn.)

Chitosan (CHT) is a natural compound that has been used to control postharvest pathogenic diseases due to its capability of eliciting natural defense responses in plants. The aim of this study was to investigate the effect of foliar CHT application on yield and quality of the litchi fruit. Chitosan was applied by spraying on to fruit and foliage just after fruit set four times at 7-day intervals with four varying doses viz. 100, 250, 500, and 1,000 µg L−1 and a control (0 µg L−1). Although the application of CHT had no significant effect on the size of the fruits (length and width), the total contents of phenolics, flavonoids, and ascorbic acid and the antioxidant activity of litchi fruit arils were significantly increased in CHT-treated fruit compared with the untreated control. The highest phenolic, flavonoid, and ascorbic acid contents were 334 µg gallic acid g−1, 881 μg quercetin g−1, and 178 µg g−1, respectively, in fruits treated with 500 µg L−1 CHT. However, the highest antioxidant activity (622 μg butylated hydroxytoluene g−1) was recorded in 250 µg L−1 CHT-treated fruits. Our findings revealed that the application of low doses of CHT in a litchi orchard might improve fruit quality by increasing the content of antioxidants and antioxidant activities

Balancing Selection at the Tomato RCR3 Guardee Gene Family Maintains Variation in Strength of Pathogen Defense

Coevolution between hosts and pathogens is thought to occur between interacting molecules of both species. This results in the maintenance of genetic diversity at pathogen antigens (or so-called effectors) and host resistance genes such as the major histocompatibility complex (MHC) in mammals or resistance (R) genes in plants. In plant-pathogen interactions, the current paradigm posits that a specific defense response is activated upon recognition of pathogen effectors via interaction with their corresponding R proteins. According to the''Guard-Hypothesis,'' R proteins (the ``guards'') can sense modification of target molecules in the host (the ``guardees'') by pathogen effectors and subsequently trigger the defense response. Multiple studies have reported high genetic diversity at R genes maintained by balancing selection. In contrast, little is known about the evolutionary mechanisms shaping the guardee, which may be subject to contrasting evolutionary forces. Here we show that the evolution of the guardee RCR3 is characterized by gene duplication, frequent gene conversion, and balancing selection in the wild tomato species Solanum peruvianum. Investigating the functional characteristics of 54 natural variants through in vitro and in planta assays, we detected differences in recognition of the pathogen effector through interaction with the guardee, as well as substantial variation in the strength of the defense response. This variation is maintained by balancing selection at each copy of the RCR3 gene. Our analyses pinpoint three amino acid polymorphisms with key functional consequences for the coevolution between the guardee (RCR3) and its guard (Cf-2). We conclude that, in addition to coevolution at the ``guardee-effector'' interface for pathogen recognition, natural selection acts on the ``guard-guardee'' interface. Guardee evolution may be governed by a counterbalance between improved activation in the presence and prevention of auto-immune responses in the absence of the corresponding pathogen

Diversifying Implementation Science: A Global Perspective.

We present a joint global perspective about the urgent need to diversify the loci of knowledge creation and sharing in global implementation science. We underscore the imperative of addressing implementation research questions relevant to practitioners, policy makers, and researchers from low- and middle-income countries

Fine Pathogen Discrimination within the APL1 Gene Family Protects Anopheles gambiae against Human and Rodent Malaria Species

Genetically controlled resistance of Anopheles gambiae mosquitoes to Plasmodium falciparum is a common trait in the natural population, and a cluster of natural resistance loci were mapped to the Plasmodium-Resistance Island (PRI) of the A. gambiae genome. The APL1 family of leucine-rich repeat (LRR) proteins was highlighted by candidate gene studies in the PRI, and is comprised of paralogs APL1A, APL1B and APL1C that share ≥50% amino acid identity. Here, we present a functional analysis of the joint response of APL1 family members during mosquito infection with human and rodent Plasmodium species. Only paralog APL1A protected A. gambiae against infection with the human malaria parasite P. falciparum from both the field population and in vitro culture. In contrast, only paralog APL1C protected against the rodent malaria parasites P. berghei and P. yoelii. We show that anti-P. falciparum protection is mediated by the Imd/Rel2 pathway, while protection against P. berghei infection was shown to require Toll/Rel1 signaling. Further, only the short Rel2-S isoform and not the long Rel2-F isoform of Rel2 confers protection against P. falciparum. Protection correlates with the transcriptional regulation of APL1A by Rel2-S but not Rel2-F, suggesting that the Rel2-S anti-parasite phenotype results at least in part from its transcriptional control over APL1A. These results indicate that distinct members of the APL1 gene family display a mutually exclusive protective effect against different classes of Plasmodium parasites. It appears that a gene-for-pathogen-class system orients the appropriate host defenses against distinct categories of similar pathogens. It is known that insect innate immune pathways can distinguish between grossly different microbes such as Gram-positive bacteria, Gram-negative bacteria, or fungi, but the function of the APL1 paralogs reveals that mosquito innate immunity possesses a more fine-grained capacity to distinguish between classes of closely related eukaryotic pathogens than has been previously recognized

Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol.

Background: Typhoid and paratyphoid fever (enteric fever) is a common cause of non-specific febrile infection in adults and children presenting to health care facilities in low resource settings such as the South Asia.  A 7-day course of a single oral antimicrobial such as ciprofloxacin, cefixime, or azithromycin is commonly used for its treatment. Increasing antimicrobial resistance threatens the effectiveness of these treatment choices. We hypothesize that combined treatment with azithromycin (active mainly intracellularly) and cefixime (active mainly extracellularly) will be a better option for the treatment of clinically suspected and culture-confirmed typhoid fever in South Asia. Methods: This is a phase IV, international multi-center, multi-country, comparative participant-and observer-blind, 1:1 randomised clinical trial. Patients with suspected uncomplicated typhoid fever will be randomized to one of the two interventions: Arm A: azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) and cefixime 20mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days, Arm B: azithromycin 20mg/kg/day oral dose once daily (max 1gm/day) for 7 days AND cefixime-matched placebo for 7 days. We will recruit 1500 patients across sites in Bangladesh, India, Nepal, and Pakistan. We will assess whether treatment outcomes are better with the combination after one week of treatment and at one- and three-months follow-up. Discussion: Combined treatment may limit the emergence of resistance if one of the components is active against resistant sub-populations not covered by the other antimicrobial activity. If the combined treatment is better than the single antimicrobial treatment, this will be an important result for patients across South Asia and other typhoid endemic areas. Clinicaltrials.gov registration: NCT04349826 (16/04/2020)